长风药业（香港交易所代码：2652.HK）宣布，其潜在同类首创（First-in-Class）吸入干粉制剂候选药物ICF004的新药临床试验（IND）申请，已获得国家药品监督管理局（NMPA）的受理。ICF004旨在针对进行性纤维化性间质性肺病（PF-ILD）领域存在的未满足临床需求。
长风药业（香港交易所代码：2652.HK）宣布，其潜在同类首创（First-in-Class）吸入干粉制剂候选药物ICF004的新药临床试验（IND）申请，已获得国家药品监督管理局（NMPA）的受理。ICF004旨在针对进行性纤维化性间质性肺病（PF-ILD）领域存在的未满足临床需求。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.